WO1999057535A3 - Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression - Google Patents

Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression Download PDF

Info

Publication number
WO1999057535A3
WO1999057535A3 PCT/US1999/009793 US9909793W WO9957535A3 WO 1999057535 A3 WO1999057535 A3 WO 1999057535A3 US 9909793 W US9909793 W US 9909793W WO 9957535 A3 WO9957535 A3 WO 9957535A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant cell
identifying agents
cell line
screening method
tumor suppression
Prior art date
Application number
PCT/US1999/009793
Other languages
French (fr)
Other versions
WO1999057535A2 (en
Inventor
Eileen White
Anju Thomas
Gary Kasof
Lakshmi Goyal
Original Assignee
Univ Rutgers
Eileen White
Anju Thomas
Gary Kasof
Lakshmi Goyal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers, Eileen White, Anju Thomas, Gary Kasof, Lakshmi Goyal filed Critical Univ Rutgers
Priority to AU38816/99A priority Critical patent/AU3881699A/en
Priority to US09/674,876 priority patent/US6890716B1/en
Publication of WO1999057535A2 publication Critical patent/WO1999057535A2/en
Publication of WO1999057535A3 publication Critical patent/WO1999057535A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

This invention provides recombinant cell lines and screening methods useful for identifying agents that induce apoptosis in target cells and therefore may be used to advantage in the treatment of neoplastic disorders.
PCT/US1999/009793 1998-05-07 1999-05-06 Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression WO1999057535A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU38816/99A AU3881699A (en) 1998-05-07 1999-05-06 Recombinant cell line and screening method for identifying agents which regulateapoptosis and tumor suppression
US09/674,876 US6890716B1 (en) 1998-05-07 1999-05-06 Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US8466498P 1998-05-07 1998-05-07
US60/084,664 1998-05-07
US9139198P 1998-07-01 1998-07-01
US60/091,391 1998-07-01
US9287198P 1998-07-15 1998-07-15
US60/092,871 1998-07-15
US10768998P 1998-11-09 1998-11-09
US60/107,689 1998-11-09

Publications (2)

Publication Number Publication Date
WO1999057535A2 WO1999057535A2 (en) 1999-11-11
WO1999057535A3 true WO1999057535A3 (en) 2000-01-06

Family

ID=27491883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009793 WO1999057535A2 (en) 1998-05-07 1999-05-06 Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression

Country Status (1)

Country Link
WO (1) WO1999057535A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820863D0 (en) 2018-12-20 2019-02-06 Univ Bath Screening assay

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691179A (en) * 1993-08-26 1997-11-25 Washington University Cell death regulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691179A (en) * 1993-08-26 1997-11-25 Washington University Cell death regulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARANY Z., ET AL.: "AN ESSENTIAL ROLE FOR P300/CBP IN THE CELLULAR RESPONSE TO HYPOXIA.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 93., 1 November 1996 (1996-11-01), US, pages 12969 - 12973., XP002922427, ISSN: 0027-8424, DOI: 10.1073/pnas.93.23.12969 *
KASOF G. M., GOYAL L., WHITE E.: "BTF, A NOVEL DEATH-PROMOTING TRANSCRIPTIONAL REPRESSOR THAT INTERACTS WITH BCL-2-RELATED PROTEINS.", MOLECULAR AND CELLULAR BIOLOGY., AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON., US, vol. 19., no. 06., 1 June 1999 (1999-06-01), US, pages 4390 - 4404., XP002922429, ISSN: 0270-7306 *
MANNERVIK M., AKUSJAERVI G.: "THE TRANSCRIPTIONAL CO-ACTIVATOR PROTEINS P300 AND CBP STIMULATE ADENOVIRUS E1A CONSERVED REGION 1 TRANSACTIVATION INDEPENDENT OF A DIRECT INTERACTION.", FEBS LETTERS., ELSEVIER, AMSTERDAM., NL, vol. 414., 1 January 1997 (1997-01-01), NL, pages 111 - 116., XP002922426, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(97)00982-4 *
THOMAS A., WHITE E.: "SUPPRESSION OF THE P300-DEPENDENT MDM2 NEGATIVE-FEEDBACK LOOP INDUCES THE P53 APOPTOTIC FUNCTION.", GENES AND DEVELOPMENT., COLD SPRING HARBOR LABORATORY PRESS, PLAINVIEW, NY., US, vol. 12., 1 January 1998 (1998-01-01), US, pages 1975 - 1985., XP002922428, ISSN: 0890-9369 *

Also Published As

Publication number Publication date
WO1999057535A2 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
AU8296098A (en) Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
AU2003278792A8 (en) Method and system for improving the liquidity of transactions
AU4317799A (en) Method and system for the computerized assessment of breast cancer risk
WO2004048551A3 (en) Target for therapy of cognitive impairment
AU2998000A (en) Method of creating and preserving the identity of non-genetically modified seedsand grains
HUP0003964A2 (en) Methods for treating thrombotic disorders
HU9803018D0 (en) Methods and compositions for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
HK1037722A1 (en) Modulating multiple lineage kinase proteins.
WO2003077848A3 (en) Jagged 2 inhibitors for inducing apoptosis
MXPA01011923A (en) Compositions and methods for treating cell proliferation disorders.
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
WO1999057535A3 (en) Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression
NO20013146L (en) Means for the treatment of visual cell dysfunction
IL189502A0 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2004038371A3 (en) Ccr8 as modifier of branching morphogenesis and methods of use
AU2002219830A1 (en) Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
WO2000012754A8 (en) Method for identifying substances for the treatment of c-jun-mediated disorders
IL139303A0 (en) Treatment of arthritis and other similar conditions
AU2393500A (en) Method for preventing and treating the degeneration of neurons
WO2001043694A3 (en) Compositions and methods for caspase-induced apoptosis
WO2004036181A3 (en) Method of treating neurological diseases and disorders
AP2000001958A0 (en) Paroxetine 10-camphorsulfornate for treatment of CNS disorders.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 09674876

Country of ref document: US